Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Financial Officer | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 256,725 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Sale · Disposed 3,115 · Balance 256,725 F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 20, 2026 23:13 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,115 | $13.04 | $40,619.60 |
DisclosureSEC source: 0001780662-26-000013 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,725 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 11, 2026 Filed Mar 14, 2026 00:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,672 | $13.17 | $245,910.24 |
DisclosureSEC source: 0001780662-26-000006 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,840 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 61,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001780662-26-000004 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,512 Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 00:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,145 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780662-26-000002 · primary_doc.xml · derivative · entry 3 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,146 Underlying: Common Stock · 2,145 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 00:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,145 | $18.46 | $39,596.70 |
DisclosureSEC source: 0001780662-26-000002 · primary_doc.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,637 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 00:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,145 | $12.14 | $26,040.30 |
DisclosureSEC source: 0001780662-26-000002 · primary_doc.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 4,290 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780662-26-000001 · primary_doc.xml · derivative · entry 3 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,291 Underlying: Common Stock · 4,290 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,290 | $18.00 | $77,220.00 |
DisclosureSEC source: 0001780662-26-000001 · primary_doc.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,637 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:17 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 4,290 | $12.14 | $52,080.60 |
DisclosureSEC source: 0001780662-26-000001 · primary_doc.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 94,384 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 7 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,581 Underlying: Common Stock · 94,384 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 6 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,980 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · derivative · entry 5 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,980 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 162,820 | $19.50 | $3,174,990.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 4 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,637 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $19.28 to $19.72, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 94,384 | $12.14 | $1,145,821.76 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 3 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,750 | $7.80 | $29,250.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 285,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,980 | $6.55 | $78,469.00 |
DisclosureSEC source: 0001780662-25-000003 · primary_doc.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 00:14 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 238 | $14.05 | $3,343.90 |
DisclosureSEC source: 0001780662-25-000002 · primary_doc.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,343 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2025 Filed May 19, 2025 23:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,929 | $8.89 | $17,148.81 |
DisclosureSEC source: 0001062993-25-009837 · form4.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,396 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 16, 2025 Filed May 20, 2025 23:46 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,929 | $8.89 | $17,148.81 |
DisclosureSEC source: 0001062993-25-009904 · form4a.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,581 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 15, 2025 Filed May 19, 2025 23:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 7,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009837 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,325 Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001062993-25-005645 · form4.xml · derivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 23:34 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,500 | $6.32 | $15,800.00 |
DisclosureSEC source: 0001062993-25-005645 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:20 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,964 | $6.99 | $48,678.36 |
DisclosureSEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 4 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,010 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:20 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 253 | $6.98 | $1,765.94 |
DisclosureSEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 3 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,974 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:20 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,103 | $6.97 | $21,627.91 |
DisclosureSEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,227 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:20 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004813 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,330 Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 23:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 248 | $4.98 | $1,235.04 |
DisclosureSEC source: 0001062993-24-019373 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,330 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:35 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 31,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010709 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,578 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:43 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,727 | $3.43 | $26,503.61 |
DisclosureSEC source: 0001062993-24-005768 · form4.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,318 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:43 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 43,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005768 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,045 Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 22:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 259 | $4.13 | $1,069.67 |
DisclosureSEC source: 0001062993-23-021224 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,305 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 229 | $8.58 | $1,964.82 |
DisclosureSEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 3 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,564 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,300 | $8.57 | $28,281.00 |
DisclosureSEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,793 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 43,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006330 · form4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,093 Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 11:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 959 | $8.87 | $8,506.33 |
DisclosureSEC source: 0001209191-22-057432 · doc4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,706 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:15 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 307 | $8.87 | $2,723.09 |
DisclosureSEC source: 0001209191-22-057531 · doc4a.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,358 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding olbigaitons to e funded by a sell to cover transaction and does not represent a discretionary trade. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 220 | $12.01 | $2,642.20 |
DisclosureSEC source: 0001209191-22-017396 · doc4.xml · nonDerivative · entry 2 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,665 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 102,965 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017396 · doc4.xml · derivative · entry 3 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,965 Underlying: Common Stock · 102,965 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 41,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017396 · doc4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,885 Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 9,592 | $0.00 Strike: $32.58 | $0.00 |
DisclosureSEC source: 0001209191-21-065312 · doc4.xml · derivative · entry 2 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,592 Underlying: Common Stock · 9,592 shares Expires 2031-11-15 F1 · derivative.exercise_date: The option will vest with respect to 1/4 of such shares on November 15, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 3,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065312 · doc4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,699 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.